Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baxter International's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN29,890 Mil.
Baxter International's quarterly Current Accrued Expense
increased
from Dec. 2025 (MXN17,988 Mil) to Mar. 2026 (MXN31,828 Mil) but then
declined
from Mar. 2026 (MXN31,828 Mil) to Jun. 2026 (MXN29,890 Mil).
Baxter International's annual Current Accrued Expense
increased
from Dec. 2023 (MXN13,291 Mil) to Dec. 2024 (MXN15,600 Mil) and
increased
from Dec. 2024 (MXN15,600 Mil) to Dec. 2025 (MXN17,988 Mil).
Baxter International Current Accrued Expense Related Terms
Baxter International Current Accrued Expense Historical Data
* Premium members only.
The historical data trend for Baxter International's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International Current Accrued Expense Chart
Baxter International Current Accrued Expense Calculation
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of MXN29,890 Mil mean?
Baxter International (MEX:BAX) has a Current Accrued Expense of MXN29,890 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Baxter International and its competitors.
Is Baxter International's Current Accrued Expense too high?
Baxter International's current Current Accrued Expense is MXN29,890 Mil. Overall, Baxter International has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Baxter International's Current Accrued Expense compare to ALGN and SOLV?
Baxter International's Current Accrued Expense of MXN29,890 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Baxter International and its competitors. Baxter International's current Current Accrued Expense is MXN29,890 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (MEX:BAX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN563.08, compared to a current price of MXN427.50 — trading 24.1% below its estimated fair value. The current Current Accrued Expense is MXN29,890 Mil. Baxter International's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Baxter International (MEX:BAX), the current Current Accrued Expense is MXN29,890 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (MEX:BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of MXN427.50 is trading 24.1% below its estimated GF Value™ of MXN563.08.
GuruFocus considers Baxter International to be Modestly Undervalued.
Key valuation signals for MEX:BAX:
Current Accrued Expense: MXN29,890 Mil
GF Value™: MXN563.08 vs. price of MXN427.50 (24.1% below fair value)
No single metric tells the full story. See the MEX:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
52GF Score
Get the complete analysis for MEX:BAX
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BAX has been successfully added to your 
